Characteristic gene expression in the liver monocyte-macrophage-DC system is associated with the progression of fibrosis in NASH

Background The monocyte-macrophage-dendritic cell (DC) (MMD) system exerts crucial functions that may modulate fibrogenesis in nonalcoholic steatohepatitis (NASH). In this study, we explored the cell characteristics, distribution and developmental trajectory of the liver MMD system in NASH mice with fibrosis and clarified characteristic genes of the MMD system involved in liver fibrosis progression in NASH mice and patients. Methods Single cells in liver tissue samples from NASH and normal mice were quantified using single-cell RNA sequencing (scRNA-seq) analysis. Differentially expressed genes (DEGs) in the MMD system by pseudotime analysis were validated by tyramide signal amplification (TSA)-immunohistochemical staining (IHC) and analyzed by second harmonic generation (SHG)/two-photon excitation fluorescence (TPEF). Results Compared with control mice, there were increased numbers of monocytes, Kupffer cells, and DCs in two NASH mouse models. From the transcriptional profiles of these single cells, we identified 8 monocyte subsets (Mono1-Mono8) with different molecular and functional properties. Furthermore, the pseudotime analysis showed that Mono5 and Mono6 were at the beginning of the trajectory path, whereas Mono2, Mono4, Kupffer cells and DCs were at a terminal state. Genes related to liver collagen production were at the late stage of this trajectory path. DEGs analysis revealed that the genes Fmnl1 and Myh9 in the MMD system were gradually upregulated during the trajectory. By TSA-IHC, the Fmnl1 and Myh9 expression levels were increased and associated with collagen production and fibrosis stage in NASH mice and patients. Conclusions Our transcriptome data provide a novel landscape of the MMD system that is involved in advanced NASH disease status. Fmnl1 and Myh9 expression in the MMD system was associated with the progression of NASH fibrosis.

[1]  H. Qin,et al.  The versatility of macrophage heterogeneity in liver fibrosis , 2022, Frontiers in Immunology.

[2]  B. Türköz,et al.  Bioinformatic Analysis , 2022, Bioactive Peptides from Food.

[3]  Lu Zhou,et al.  Identification of Key Genes and Immune Infiltrate in Nonalcoholic Steatohepatitis: A Bioinformatic Analysis , 2021, BioMed research international.

[4]  Chunhong Ma,et al.  The hepatic macrophage pool in NASH , 2021, Cellular & Molecular Immunology.

[5]  Dongmei Wang,et al.  Identification of transcriptomic signatures and crucial pathways involved in non-alcoholic steatohepatitis , 2021, Endocrine.

[6]  M. Petroni,et al.  Management of non-alcoholic fatty liver disease , 2021, BMJ.

[7]  Sachiyo Yoshio,et al.  Macrophages as a source of fibrosis biomarkers for non-alcoholic fatty liver disease , 2021, Immunological medicine.

[8]  F. Tacke,et al.  Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention , 2020, Annals of translational medicine.

[9]  Y. Saeys,et al.  Osteopontin Expression Identifies a Subset of Recruited Macrophages Distinct from Kupffer Cells in the Fatty Liver , 2020, Immunity.

[10]  M. Vicente-Manzanares,et al.  Linking the Landscape of MYH9-Related Diseases to the Molecular Mechanisms that Control Non-Muscle Myosin II-A Function in Cells , 2020, Cells.

[11]  C. Glass,et al.  Niche-Specific Reprogramming of Epigenetic Landscapes Drives Myeloid Cell Diversity in Nonalcoholic Steatohepatitis. , 2020, Immunity.

[12]  Hongliang Li,et al.  Hepatic Regulator of G protein Signaling 5 Ameliorates NAFLD by Suppressing TAK1-JNK/p38 Signaling. , 2020, Hepatology.

[13]  K. Natarajan,et al.  Transcriptional Dynamics of Hepatic Sinusoid‐Associated Cells After Liver Injury , 2020, Hepatology.

[14]  Ai-min Li,et al.  Silencing MYH9 blocks HBx-induced GSK3β ubiquitination and degradation to inhibit tumor stemness in hepatocellular carcinoma , 2020, Signal Transduction and Targeted Therapy.

[15]  N. Bhala,et al.  Association Between Fibrosis Stage and Outcomes of Patients with Non-Alcoholic Fatty Liver Disease: a Systematic Review and Meta-Analysis. , 2020, Gastroenterology.

[16]  Z. Goodman,et al.  The Natural History of Advanced Fibrosis Due to Nonalcoholic Steatohepatitis: Data From the Simtuzumab Trials , 2019, Hepatology.

[17]  A. Schmitt-Graeff,et al.  The transcription factor c-Jun/AP-1 promotes liver fibrosis during non-alcoholic steatohepatitis by regulating Osteopontin expression , 2019, Cell Death & Differentiation.

[18]  D. Schuppan,et al.  The role of macrophages in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis , 2018, Nature Reviews Gastroenterology & Hepatology.

[19]  B. Walzog,et al.  A Fundamental Role of Myh9 for Neutrophil Migration in Innate Immunity , 2018, The Journal of Immunology.

[20]  Antonio Felix Conde-Martin,et al.  Fibrosis Severity as a Determinant of Cause-Specific Mortality in Patients With Advanced Nonalcoholic Fatty Liver Disease: A Multi-National Cohort Study. , 2018, Gastroenterology.

[21]  B. Neuschwander‐Tetri,et al.  Mechanisms of NAFLD development and therapeutic strategies , 2018, Nature Medicine.

[22]  T. Luedde,et al.  Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis , 2018, Hepatology.

[23]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[24]  A. Diehl,et al.  Cause, Pathogenesis, and Treatment of Nonalcoholic Steatohepatitis , 2017, The New England journal of medicine.

[25]  F. Tacke,et al.  Liver Fibrosis: From Pathogenesis to Novel Therapies , 2016, Digestive Diseases.

[26]  F. Tacke,et al.  Hepatic macrophages in homeostasis and liver diseases: from pathogenesis to novel therapeutic strategies , 2016, Cellular and Molecular Immunology.

[27]  E. Albano,et al.  CX3CR1-expressing inflammatory dendritic cells contribute to the progression of steatohepatitis. , 2015, Clinical science.

[28]  M. Uribe,et al.  The Role of Dendritic Cells in Fibrosis Progression in Nonalcoholic Fatty Liver Disease , 2015, BioMed research international.

[29]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[30]  S. Blystone,et al.  Human Macrophages Utilize the Podosome Formin FMNL1 for Adhesion and Migration. , 2015, CellBio.

[31]  F. Geissmann,et al.  Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors , 2014, Nature.

[32]  M. Uhlén,et al.  Characterization of Leukocyte Formin FMNL1 Expression in Human Tissues , 2014, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[33]  C. Hunter,et al.  Contractile forces sustain and polarize hematopoiesis from stem and progenitor cells. , 2014, Cell stem cell.

[34]  Adeeb H. Rahman,et al.  Dendritic cells and liver fibrosis. , 2013, Biochimica et biophysica acta.

[35]  T. Ide,et al.  A novel JNK2/SREBP-1c pathway involved in insulin-induced fatty acid synthesis in human adipocytes , 2013, Journal of Lipid Research.

[36]  S. Blystone,et al.  The multiplicity of human formins: Expression patterns in cells and tissues , 2013, Cytoskeleton.

[37]  K. Kowdley,et al.  Dendritic cells in NASH: friend or foe? , 2013, Annals of hepatology.

[38]  F. Urano,et al.  Cdc42 and Rac1 are major contributors to the saturated fatty acid-stimulated JNK pathway in hepatocytes. , 2012, Journal of hepatology.

[39]  D. Billadeau,et al.  Dynamic remodeling of the actin cytoskeleton by FMNL1γ is required for structural maintenance of the Golgi complex , 2011, Journal of Cell Science.

[40]  L. Kenner,et al.  Osteopontin deficiency protects against obesity-induced hepatic steatosis and attenuates glucose production in mice , 2011, Diabetologia.

[41]  S. Blystone,et al.  The formin FRL1 (FMNL1) is an essential component of macrophage podosomes , 2010, Cytoskeleton.

[42]  Pilar M. Dominguez,et al.  Differentiation and function of mouse monocyte‐derived dendritic cells in steady state and inflammation , 2010, Immunological reviews.

[43]  D. Bar-Sagi,et al.  In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. , 2009, The Journal of clinical investigation.

[44]  Miguel Vicente-Manzanares,et al.  Non-muscle myosin II takes centre stage in cell adhesion and migration , 2009, Nature Reviews Molecular Cell Biology.

[45]  K. Clément,et al.  Elevated Expression of Osteopontin May Be Related to Adipose Tissue Macrophage Accumulation and Liver Steatosis in Morbid Obesity , 2009, Diabetes.

[46]  D. Busch,et al.  Allorestricted T cells with specificity for the FMNL1-derived peptide PP2 have potent antitumor activity against hematologic and other malignancies. , 2007, Blood.

[47]  A. Savoia,et al.  Correlation between the clinical phenotype of MYH9-related disease and tissue distribution of class II nonmuscle myosin heavy chains. , 2004, Genomics.

[48]  James G Kench,et al.  Long‐term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C , 2003, Hepatology.

[49]  I. Taniuchi,et al.  FRL, a Novel Formin-Related Protein, Binds to Rac and Regulates Cell Motility and Survival of Macrophages , 2000, Molecular and Cellular Biology.

[50]  J. Ludwig,et al.  Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease. , 1980, Mayo Clinic proceedings.